SCHEMBL4418912

SCHEMBL4418912

O=C(NCC1C2CN(Cc3ccc(OCc4ccccc4)cc3)CC12)c1ccc(N2CCOCC2)c(F)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM4 P08173 2/20 0.48
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
USP30 Q70CQ3 1/20 0.46
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
S1PR5 Q9H228 2/20 0.45
TP53 P04637 1/20 0.45
HPGD P15428 1/20 0.45
ALOX15 P16050 1/20 0.45
TSHR P16473 1/20 0.45
MAPK1 P28482 1/20 0.45
EGFR P00533 2/20 0.44
SLC6A5 Q9Y345 1/20 0.44
ALDH1A1 P00352 4/20 0.44
MAPT P10636 2/20 0.44
GAA P10253 1/20 0.44
MAPK14 Q16539 1/20 0.42
PRKAA2 P54646 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4419241 0.92 USP30 (0.53) MEN1KMT2AUSP30NPC1RAB9A
SCHEMBL6506968 0.90 CACNA1B (0.52) MEN1KMT2AUSP30NPC1SMN1; SMN2
SCHEMBL4421358 0.89 USP30 (0.50) MEN1KMT2AUSP30NPC1RAB9A
SCHEMBL4422662 0.88 USP30 (0.46) KMT2AUSP30NPC1RAB9ASMN1; SMN2
SCHEMBL4413697 0.87 USP30 (0.53) MEN1KMT2AUSP30NPC1RAB9A
SCHEMBL4552123 0.86 USP30 (0.52) MEN1KMT2AUSP30NPC1RAB9A
SCHEMBL4415735 0.86 USP30 (0.49) KMT2AUSP30NPC1RAB9ASMN1; SMN2
SCHEMBL4412120 0.85 USP30 (0.51) KMT2AUSP30NPC1RAB9ASMN1; SMN2
SCHEMBL4419281 0.85 USP30 (0.51) USP30NPC1RAB9ASMN1; SMN2TP53
SCHEMBL4415679 0.85 USP30 (0.50) CHRM4USP30NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1680124-B1 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2017-05-31 EP claimed
EP-1680124-A4 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2009-05-13 EP claimed
JP-2007508374-A 2007-04-05 JP claimed
EP-1680124-A2 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS Pfizer Products Incorporated (US) 2006-07-19 EP claimed
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC. 2005-05-05 US claimed
WO-2005037216-A2 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PRODUCTS INC. (US) 2005-04-28 WO claimed
EP-1680124-B1 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2017-05-31 EP disclosed
US-7473787-B2 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC (US) 2009-01-06 US disclosed
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC. 2005-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors SLC6A5, SLC1A5, SLC6A3 CHRM4 256/4885MEN1 4107/4885KMT2A 1892/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.